Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

Mon, 01/15/2018 - 8:29am

AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage...

      Related Stories 

Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

Mon, 01/15/2018 - 8:29am

AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage...

      Related Stories 

Roxadustat To Overtake Epogen In Treating Anemia In CKD By 2021

Mon, 01/15/2018 - 6:37am

The market for the treatment of anemia in chronic kidney disease will see Epogen eroded by biosimilars before the overall...

      Related Stories 

Roxadustat To Overtake Epogen In Treating Anemia In CKD By 2021

Mon, 01/15/2018 - 6:37am

The market for the treatment of anemia in chronic kidney disease will see Epogen eroded by biosimilars before the overall...

      Related Stories 

Allergan, Shire Battle In Dry Eye As Generics Advance

Mon, 01/15/2018 - 4:05am

Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending...

      Related Stories 

Allergan, Shire Battle In Dry Eye As Generics Advance

Mon, 01/15/2018 - 4:05am

Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending...

      Related Stories 

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

Mon, 01/15/2018 - 3:53am

Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II...

      Related Stories 

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

Mon, 01/15/2018 - 3:53am

Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II...

      Related Stories 

Forty Seven's IO Antibody Attracts Two Big Pharma Partners

Mon, 01/15/2018 - 2:30am

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several...

      Related Stories 

Putting Innovation In The Spotlight

Fri, 01/12/2018 - 1:15pm

The Clinical and Research Excellence (CARE) Awards are Informa Pharma Intelligence's way of honoring the R&D accomplishments across the biopharmaceutical...

      Related Stories 

Tech Transfer Roundup: Mustang, Juno Advance Efforts With Immuno-Oncology

Thu, 01/11/2018 - 1:48pm

While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson...

      Related Stories 

Reflections From J.P. Morgan: Challenges As Always And Reasons For Optimism

Thu, 01/11/2018 - 9:18am

Biopharma investors were underwhelmed by the deal-making news, but innovation, corporate tax reform and a relatively positive outlook on drug...

      Related Stories 

Reflections From J.P. Morgan: Challenges As Always And Reasons For Optimism

Thu, 01/11/2018 - 9:18am

Biopharma investors were underwhelmed by the deal-making news, but innovation, corporate tax reform and a relatively positive outlook on drug...

      Related Stories 

Pages